Quantcast

Latest H5N1 clinical trials Stories

2010-10-25 07:45:00

SWIFTWATER, Pa., Oct. 25 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the results of a clinical trial of its investigational Fluzone® Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual...

2010-10-25 07:45:00

SWIFTWATER, Pa., Oct. 25 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the results of the Phase III clinical trial of its investigational Fluzone® Intradermal (Influenza Virus Vaccine) candidate compared to Fluzone (Influenza Virus Vaccine) administered via the traditional intramuscular method (IM). Data from the clinical trial assessing the immunogenicity and safety of the investigational...

2010-10-18 06:30:00

ATLANTA, Oct. 18 /PRNewswire/ -- Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN). In the article, titled "Search for Effective HIV Vaccine Intensifies: Progress to Date Result of Robust Funding and Cooperation...

2010-10-08 14:00:00

SWIFTWATER, Pa., Oct. 8 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has been awarded a three-year contract for $56.94 million by the U.S. Department of Health and Human Services (HHS) to maintain flocks to enable manufacturing pandemic influenza vaccine at full capacity on a year-round basis. The contract supported by the HHS Biomedical Advanced Research and Development Authority (BARDA) affords rapid response and...

2010-10-07 00:15:00

LA JOLLA, Calif., Oct. 7 /PRNewswire/ -- The company Synthetic Genomics Inc. (SGI) and the not-for-profit research organization, the J. Craig Venter Institute (JCVI) today announced the formation of a new company, Synthetic Genomics Vaccines Inc. (SGVI). The privately held company will focus on developing next generation vaccines using JCVI's genomic sequencing and synthetic genomic research expertise, coupled with the intellectual property and business acumen of SGI, to significantly...

2010-10-06 06:58:00

GAITHERSBURG, Md., Oct. 6 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has executed its first option period (year two) under a previously announced four year-contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). GenVec will receive up to approximately $3.5 million for...

2010-10-01 06:30:00

ATLANTA, Oct. 1 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, presented the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference held in Atlanta from September 28 to October 1. The talk, given on Thursday, September 30 in...

2010-09-30 19:43:24

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women. The Phase 3 trial, sponsored by GlaxoSmithKline (GSK) Biologicals, based in Belgium, with support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, began in 2002. A total of 8,323 women aged 18-30...

2010-09-27 11:12:00

LYON, France, September 27, 2010 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY) announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system. VaxDesign is the developer of the Modular IMmune In-vitro Construct (MIMIC(R))...

2010-09-27 06:30:00

ATLANTA, Sept. 27 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, will present the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference to be held in Atlanta from September 28 to October 1. The talk, to be given on Thursday,...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related